Last reviewed · How we verify
Xospata
At a glance
| Generic name | Xospata |
|---|---|
| Also known as | Gilteritinib |
| Sponsor | French Innovative Leukemia Organisation |
| Target | ADP/ATP translocase 2, ADP/ATP translocase 3, Bone morphogenetic protein receptor type-1B |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute myeloid leukemia, disease
Common side effects
- Transaminase increased
- Myalgia/arthralgia
- Fatigue/malaise
- Fever
- Mucositis
- Edema
- Rash
- Noninfectious diarrhea
- Dyspnea
- Nausea
- Cough
- Constipation
Serious adverse events
- Transaminase increased
- Dyspnea
- Hypotension
- Mucositis
- Myalgia/arthralgia
- Fatigue/malaise
- Fever
- Renal impairment
- Noninfectious diarrhea
- Cardiac arrest
Key clinical trials
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) (PHASE1)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML (PHASE1, PHASE2)
- SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xospata CI brief — competitive landscape report
- Xospata updates RSS · CI watch RSS
- French Innovative Leukemia Organisation portfolio CI